je.st
news
Tag: liver
Sigma-Aldrich launches 'knock-out' way to create liver toxicity assays
2014-01-21 23:47:37| Chemicals - Topix.net
Sigma-Aldrich has teamed with Biopredic to produce genetically-modified human liver cell lines and assays it says can cut costs by reducing animal toxicology studies in drug discovery.
Tags: create
liver
launches
toxicity
Intercept Liver Drug Is A Game Changer For The Biotech Industry
2014-01-12 11:08:27| Biotech - Topix.net
Nonalcoholic steatohepatitis is liver inflammation caused by a buildup of fat in the liver.
Zyoxel Announces The Performance Of Tests By Sanofi On The Power Of 3D Liver Culture Models For More Predictive And Insightful DMPK Studies
2013-12-04 06:22:33| drugdiscoveryonline News Articles
Zyoxel, the world’s leading expert for advanced in vitro 3D liver models for drug discovery and drug testing, has announced preliminary results from a testing by Sanofi on Zyoxel’s LiverChip platform for drug metabolism and pharmacokinetic (DMPK) studies
Tags: power
performance
culture
studies
Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
2013-11-02 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of interim data from the ongoing C-WORTHY Study, a Phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, with or without twice-daily ribavirin, administered for 12 weeks to treatment-nave, non-cirrhotic pat Language: English Contact: MerckMedia:Pamela Eisele, (908) 423-5042Sarra Herzog, (908) 423-6154orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Data from Mercks Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting
2013-10-01 16:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the companys investigational oral chronic hepatitis C virus (HCV) treatments MK-5172 and MK-8742 at the 64th American Association for the Study of Liver Diseases Annual Meeting (AASLD). The meeting is scheduled to take place in Washington, D.C., Nov. 1-5, 2013. Language: English Contact: MerckMedia:Sarra Herzog, 908-423-6154orInvestor:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »